Society of Urologic Oncology Biotechnology Forum: new approaches and targets for advanced prostate cancer.
OBJECTIVE
We provide an overview of advances in molecular based therapeutic strategies for prostate cancer and summarize the studies presented at the Society of Urologic Oncology Biotechnology Forum in 2000.


METHODS
Three promising new treatment strategies are presented, and a critique of the advantages and limitations of each is offered by a leading expert in the field.


RESULTS
Treatment results and the current state of dendritic cell based immunotherapy, monoclonal antibody therapy and anti-apoptotic treatment approaches are presented.


CONCLUSIONS
Currently patients with advanced prostate carcinoma have expanded therapeutic options available in the form of molecular based phases II and III clinical trials.
Belldegrun
A
A
Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, California, USA.
Bander
N H
NH
Lerner
S P
SP
Wood
D P
DP
Pantuck
A J
AJ
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D017209:Apoptosis; D002986:Clinical Trials as Topic; D003713:Dendritic Cells; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008297:Male; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*
D000911:Antibodies, Monoclonal